Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 8/20 | 0.56 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.55 |
| ▸ | JAK3 | P52333 | 7/20 | 0.54 |
| ▸ | CDK4 | P11802 | 2/20 | 0.50 |
| ▸ | CCND1 | P24385 | 2/20 | 0.50 |
| ▸ | CCND2 | P30279 | 2/20 | 0.50 |
| ▸ | CCND3 | P30281 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4192884 | 0.90 | CDK4 (0.61) | CDK4CCND1CCND2CCND3 | |
| SCHEMBL4191302 | 0.84 | SYK (0.55) | SYKALKJAK3CDK4CCND1 | |
| SCHEMBL1783349 | 0.84 | ALK (0.55) | SYKALKJAK3CDK4CCND1 | |
| SCHEMBL4189778 | 0.82 | SYK (0.55) | SYKALKJAK3CDK4CCND1 | |
| SCHEMBL4191465 | 0.82 | JAK3 (0.56) | SYKALKJAK3CDK4CCND1 | |
| SCHEMBL4199224 | 0.82 | SYK (0.54) | SYKALKJAK3CDK4CCND1 | |
| SCHEMBL4190104 | 0.81 | SYK (0.53) | SYKALKJAK3CDK4CCND1 | |
| SCHEMBL4191908 | 0.80 | JAK3 (0.54) | SYKALKJAK3CDK4CCND1 | |
| SCHEMBL7512399 | 0.75 | CDK4 (0.81) | JAK3CDK4CCND1CCND2CCND3 | |
| SCHEMBL1783576 | 0.73 | CDK4 (0.58) | CDK4CCND1CCND2CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029145-A2 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | Novartis Ag (CH) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007140222-A2 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2007-12-06 | — | — | WO | disclosed |